Austin Top 50
Author:
Cabaletta Bio
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
May 14, 2026
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
May 4, 2026
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
April 28, 2026
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
April 27, 2026
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 23, 2026